Phreesia (NYSE:PHR) Announces Earnings Results

by · The Markets Daily

Phreesia (NYSE:PHR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.06), FiscalAI reports. The company had revenue of $129.46 million during the quarter, compared to analysts’ expectations of $129.06 million. Phreesia had a net margin of 1.85% and a return on equity of 5.13%.

Phreesia Stock Performance

Shares of NYSE:PHR traded up $0.04 during trading on Wednesday, reaching $11.88. The company had a trading volume of 699,083 shares, compared to its average volume of 1,497,891. The firm has a market capitalization of $734.33 million, a price-to-earnings ratio of 79.20 and a beta of 0.85. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76. The stock’s fifty day moving average price is $11.14 and its 200 day moving average price is $10.48. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $31.83.

Wall Street Analysts Forecast Growth

PHR has been the topic of a number of research analyst reports. Barclays reissued an “equal weight” rating and set a $10.00 price objective (down from $24.00) on shares of Phreesia in a report on Thursday, May 14th. DA Davidson restated a “buy” rating and issued a $14.00 price objective on shares of Phreesia in a research note on Thursday, May 28th. Canaccord Genuity Group dropped their price objective on Phreesia from $22.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Piper Sandler cut Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a research report on Thursday, May 28th. Finally, Weiss Ratings raised Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Nine research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $16.65.

Check Out Our Latest Research Report on PHR

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the company. Prosight Management LP acquired a new stake in shares of Phreesia in the 4th quarter worth $16,533,000. Millennium Management LLC raised its holdings in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after purchasing an additional 936,033 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Phreesia during the fourth quarter worth about $15,213,000. JPMorgan Chase & Co. lifted its position in Phreesia by 807.7% in the fourth quarter. JPMorgan Chase & Co. now owns 507,220 shares of the company’s stock valued at $8,582,000 after purchasing an additional 451,339 shares during the period. Finally, Franklin Resources Inc. lifted its position in Phreesia by 28.8% in the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after purchasing an additional 446,890 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Company Profile

(Get Free Report)

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

Further Reading